PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its proxy statement related to the announced Special Shareholder Meeting on September 11, 2019, is available on PharmaCyte’s website at: https://ir.pharmacytebiotech.com/proxy.
August 27, 2019
· 3 min read